NCT03776994 - Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

July 27, 2020

Study Completion Date

April 30, 2021

Conditions

EncephalitisEncephalitis, ViralInfectious EncephalitisVirus DiseasesEncephalomyelitis, Venezuelan EquineBrain DiseasesCentral Nervous System DiseasesCentral Nervous System Viral DiseasesAlphavirus InfectionsTogaviridae InfectionsRNA Virus InfectionsCentral Nervous System InfectionsEncephalomyelitisPhysiological Effects of DrugsVaccinesEncephalomyelitis, EquineNervous System Diseases

Interventions

BIOLOGICAL

Vaccinations on Day 0, Day 28, and Day 140

The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)

Trial Locations (1)

48170

SRI Biosciences Clinical Trials Unit, Plymouth